Ultimovacs ASA (STU:7UM) Other Gross PPE : €0.30 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Other Gross PPE?

Ultimovacs ASA's Other Gross PPE for the quarter that ended in Mar. 2024 was €0.30 Mil.

Ultimovacs ASA's quarterly Other Gross PPE declined from Sep. 2023 (€0.37 Mil) to Dec. 2023 (€0.24 Mil) but then increased from Dec. 2023 (€0.24 Mil) to Mar. 2024 (€0.30 Mil).

Ultimovacs ASA's annual Other Gross PPE increased from Dec. 2021 (€0.13 Mil) to Dec. 2022 (€0.40 Mil) but then declined from Dec. 2022 (€0.40 Mil) to Dec. 2023 (€0.24 Mil).

Ultimovacs ASA Other Gross PPE Historical Data

The historical data trend for Ultimovacs ASA's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Other Gross PPE Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

0.31

0.24

0.13

0.40

0.24

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															0.46	0.40	0.37	0.24	0.30

Ultimovacs ASA Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Ultimovacs ASA (STU:7UM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines